In Italy, the management of pharmacovigilance funds will become more efficient thanks to AIFA’s new platform. Regions will now be able to better monitor resources, improving the safety and transparency of processes.
The AIFA’s platform for the management of pharmacovigilance funds
Starting from October 1, 2024, the Italian Medicines Agency (AIFA) has made available a new digital platform for the management of pharmacovigilance funds, with the aim of improving the efficiency and traceability of processes related to post-marketing monitoring of medicines. This innovative tool is accessible to all Regions and represents a real breakthrough for Regional Pharmacovigilance Centers, facilitating smoother management of resources allocated to active surveillance projects.
A step towards digitalization: efficiency and control
The new platform replaces the previously used manual systems, which slowed down data collection and analysis. This shift to digital allows for the standardization of technical and financial data entry, simplifying the sharing and analysis of information. In this way, it will be possible to monitor each stage of the process, from funded activities to communications between various stakeholders, with continuous and automated control of deadlines thanks to integrated notifications and reminders.
Anna Rosa Marra, head of AIFA’s Post-Marketing Surveillance Area, emphasized how this tool will enable more efficient and transparent management of resources, improving coordination between Regions and AIFA itself. This will contribute to optimizing pharmacovigilance activities, ensuring more accurate control over the safety and proper use of medicines in real-world conditions.
AIFA platform: a system supporting public safety
AIFA’s new IT system has been designed to support the work of the Regional Pharmacovigilance Centers, which play a key role in post-marketing surveillance of medicines. Through continuous monitoring and optimized management of financial resources, the platform enables greater transparency and more precise control over funded activities, ensuring enhanced patient safety.
